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NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).E vidence suggests that 1.7 million persons (10% of theAustralian adult population) are living with chronic
kidney disease (CKD).1 Within the Australian CKD popu-
lation, around 10% of individuals are found to have agenetic cause for their kidney disease.2 As genomic
sequencing technology becomes more mainstreamed, the
identification of genetic kidney disease (GKD) is expected
to increase. The CKD population experiences an excess ofKidney International Reports (2020) 5, 530–541
RESEARCH LETTERSmorbidity, engagement with health services, and mortal-
ity.1 In all, 1 in 7 (16%) of 2015 to 2016 hospitalizations in
Australia were associated with CKD.1 It is yet to be clearly
establishedwhether and how individualswith CKDdue to
GKD differ from those with nonGKD-related CKD, and
whether their disease follows the same clinical trajectory.
Genetic kidney disease encompasses a vast range of
complex and heterogenous conditions; thus, establish-
ing the overall prevalence has been particularly chal-
lenging. It is most likely underestimated, particularly in
areaswith limited access to diagnostic tools and specialist
renal services. Certain monogenic nephropathies are
more commonly encountered and diagnosed, for
example, autosomal dominant polycystic kidney disease
(ADPKD) or Alport syndrome. There are, however,
conditions that are much less frequently encountered,
particularly among small populations, such as Lowe
syndrome.3 An enhanced understanding of the genetic
basis of both common and rare conditions can only lead
to improved diagnosis, clinical care, therapy, and patient
outcomes. The first step is to establish the prevalence,
disease characteristics, and demographics.
This study sought to establish the prevalence of
GKD among the CKD population that is provided
clinical care by the Southern Tasmania Renal Service.
We aimed to understand how GKD contributes to
kidney disease in our local community, to identify
unaddressed areas of clinical need, and thus to develop
health care provisions accordingly.
A multisource, retrospective audit involving sec-
ondary use of existing data was conducted. Patients
with CKD belonging to the Southern Tasmania Renal
Service were identified from AUDIT4 (Royal Hobart
Hospital renal clinic database, n ¼ 2407) and
ANZDATA (Australia and New Zealand Dialysis and
Transplantation Registry, n ¼ 361). After discarding
duplicates, the records of 2434 individuals referred to
tertiary renal services between 1 January 2012 and 31
December 2017 were reviewed. From this population,
individuals with CKD due to GKD were identified.
Genetic kidney disease was defined as any condition
with a known genetic etiology diagnosed in a patient
on clinical or molecular grounds, in line with previous
Australian prevalence studies.3 We compared the GKD
and non-GKD populations and evaluable differences in
their demographic features and clinical outcomes,
including most recent kidney function and age at
commencement of renal replacement therapy (RRT). To
establish statistical significance, continuous variables
were analyzed using the Student t test and categorical
variables with the c2 test and were considered signif-
icant if P < 0.05. The study was approved by the
Tasmania Health and Medical Research Human Ethics
Committee (Study H0017245).Kidney International Reports (2020) 5, 530–541RESULTS
In Tasmania, GKD comprised 8.5% of the CKD popu-
lation (208 of 2434 individuals). The GKD patients were
younger than the non-GKD patients (mean age 52 years
vs. 64 years, P < 0.001) and did not have a greater
tendency to be either male or female. There was no
significant difference in mean eGFR (using the Chronic
Kidney Disease Epidemiology Collaboration [CKD-EPI]
formula) (Table 1).
Patients with CKD more commonly developed CKD
stage 5 (40% vs. 17%, P < 0.001), commenced RRT
(39.4% vs. 12.3%, P < 0.001), and underwent trans-
plantation (30.3% vs. 5%, P < 0.001). Furthermore,
GKD patients who commenced RRT did so at a younger
age (mean age 46 years vs. 55 years, P< 0.001) (Table 2).
Cystic kidney disease was the most common form of
GKD (48%), followed by congenital anomalies of the
kidney and urinary tract (CAKUT) (37%). Patients with
CAKUT started RRT at younger ages than those with
cystic disease (mean age 39 years vs. 55 years, P <
0.001) (Table 3). In addition, they underwent kidney
transplantation at a younger age (mean age 36 years vs.
52 years, P < 0.001). Broadly speaking, patients with
glomerular, tubular/metabolic, or other less common
forms of GKD were more likely to be older and male. Of
the 208 patients with GKD in Southern Tasmania, only
25 (12%) were known to the Tasmanian Clinical Ge-
netics Service or had been referred for genetic testing
or counseling at the time of this audit.
DISCUSSION
In Tasmania, 8.5% of the CKD population had a condi-
tion meeting our definition of GKD. This figure reflects
that of other Australian subpopulations. For example, a
recent Queensland-based multisite CKD registry estab-
lished a GKD prevalence of 9.8% in their population.2
Ourfindings support emerging evidence that around 1 in
10 Australian patients with CKD will have an inherited
cause for their disease if investigated.2
Female and male individuals were represented
similarly, both when comparing the GKD and non-GKD
cohorts and when comparing specific types of GKD.
Previous similar studies found a greater representation
of females among their GKD population.2 Theories
behind this included the presence of autosomal con-
ditions with a higher penetrance of disease in females,
or poorer survival of males with an X-linked condition.
Among our study population, ADPKD and CAKUT
made up 85% of our GKD population, which may
explain 1 reason for our differing observation. In
addition, there are records of patients in Tasmania
treated by private nephrologists that were not accessed
for this audit.535
Table 1. Patient features: GKD versus non-GKD
GKD Non-GKD P value
Age, yr 52 64 <0.001
Female sex 51% 48% 0.4
Mean eGFR (ml/min per 1.73 m2) 49.2 45 0.12
eGFR, estimated glomerular filtration rate; GKD, genetic kidney disease.
Table 3. Specific GKD subtypes
GKD subtype n GKD cohort prevalence (%)
CAKUT 76 37
Vesicoureteric reflux 57
Renal agenesis/hypoplasia 8
Abnormalities of renal pelvis or ureter 4
Horseshoe kidney 3
Posterior urethral valves 2
Other 2
Cystic kidney disease 99 48
Polycystic kidney disease, autosomal dominant 81
Medullary cystic kidney disease 12
Other cystic kidney disease 6
Glomerular 9 4
Alport syndrome 9
Nephrolithiasis 12 6
Hypercalciuria 10
Oxalosis/cystinosis 2
Tubular/metabolic 5 2
Gitelman syndrome 3
Fabry disease 2
Other 7 3
Tuberous sclerosis complex 2
Inherited kidney cancer syndromes 2
Single cases (not further specified, for anonymity) 3
CAKUT, congenital anomalies of the kidney and urinary tract; GKD, genetic kidney
disease.
RESEARCH LETTERSOur findings show that patients with GKD-related
CKD among the Southern Tasmanian population expe-
rience greater morbidity at younger ages. In all, 40%
(n ¼ 84) of individuals with GKD progressed to RRT,
compared to only 17% (n ¼ 378) of the non-GKD
cohort. Importantly, those with GKD commenced
RRT on average 10 years younger. This reflects a
pathophysiological decline in kidney function from
birth, as opposed to the accumulation of kidney dam-
age secondary to chronic disease. Arguably, identifi-
cation of inherited CKD earlier may reflect motivation
from families with a known history to seek specialist
advice sooner. Perhaps with greater health promotion,
the age at diagnosis may become even younger.
As expected, cystic kidney disease and CAKUT
comprised a large majority of our GKD population. This
reflects other comparable CKD cohorts in Australia.2
Despite the prevalence of these conditions, tailored
approaches to patient management, including genetic
diagnosis and counseling, remain limited. We also iden-
tified rarer inherited causes of kidney disease, for example
tuberous sclerosis. This confirms that these conditions do
exist within our population, albeit in small numbers. Tu-
berous sclerosis is a condition familiar to most nephrolo-
gists and general practitioners, and it can be diagnosed
clinically.Arguably, limited clinical exposure to other rare
conditions means that a proportion of Tasmanians with
rare forms of GKD are currently undiagnosed, and they
will require genetic evaluation and testingbefore a specific
diagnosis can be made. By establishing a specialist renal
genetics service to identify at-risk individuals and to
diagnose and treat GKD, we may see a significant rise in
both common and uncommon conditions.
We found that only 12% were known to the Tasma-
nian Clinical Genetics Service or had received genetic
testing or counseling at the time of our audit. Underuse
of this valuable resource4 creates a barrier to timely,
accurate diagnosis of GKD. Patients are not accessing
appropriate specialist genetic input, which means that
they may be missing the opportunity for a specificTable 2. Clinical outcomes in patients with GKD versus non-GKD
Outcome GKD Non-GKD P value
ESKD 40% 17% <0.001
RRT 38% 12% <0.001
Transplant 30% 5% <0.001
ESKD, end-stage kidney disease; GKD, genetic kidney disease; RRT, renal replacement
therapy.
536diagnosis and an appreciation of the heritable nature of
their condition. Creating a clear link between hospital/
clinic-based management of GKD and the local genetics
service facilitates early referral, accurate diagnosis, and
appropriate counseling.5 All of these things have the
potential to significantly affect the disease trajectory for
affected individuals and their families.
This study confirms the considerable number of
patients living with GKD in Tasmania. The prevalence
of GKD among the Tasmanian CKD population reflects
findings in other Australian studies. Identifying this
population supports the development of a tailored renal
genetic service, to aid early diagnosis and to improve
clinical outcomes. Of particular value is to establish a
clear link between renal and genetic services, so as to
provide genetic testing, counseling, and education. A
genetic result has the power to minimize diagnostic
uncertainty, to inform reproductive planning, and to
avoid unnecessary biopsy in certain patients. The
resultant patient-centric goal is to ensure that patients
and families affected by GKD receive up-to-date rele-
vant care and are supported holistically.DISCLOSURE
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primary or secondary. Primary MN is most commonly
associated with antiM-type phospholipase A2receptor (PLA2R) antibodies and is usually IgG4
dominant, whereas secondary MN can be seen in the
setting of malignancies, infections, autoimmune dis-
eases, or as a side effect of certain medications or(GBM) disease (case 12) with segmental membranous nephropathy
H&E] stain, original magnification 400). (b) Silver stain shows a
the GBM (original magnification 4000). (c) Linear IgG staining
opic image showing segmental subepithelial deposits. Bottom row
8). (e) Glomerulus with a cellular crescent (H&E stain, original
(fine lucencies and spikes) in the same glomerulus that contains a
y shows diffuse granular positivity along the GBM (immunofluores-
fuse subepithelial deposits.
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